Drug-Resistant Tuberculosis Test From China's Zeesan Biotech Performs Well in Clinical Validation | GenomeWeb

NEW YORK (GenomeWeb) – A group led by researchers from the Chinese Centers for Disease Control and Prevention has published a clinical validation of Zeesan Biotech's MeltPro TB assay for the detection of multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) in patient sputum samples.

With this key validation completed, Zeesan now plans to market the test, which runs on its MeltPro system, in China, Pakistan, and Indonesia, according to Qingge Li, a professor at China's Xiamen University who works closely with Zeesan on commercial projects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.